# BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies

> **NCT06645301** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **BioSyngen Pte Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Group A
- **BIOLOGICAL:** Group B

## Key facts

- **NCT ID:** NCT06645301
- **Lead sponsor:** BioSyngen Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06645301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06645301, "BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06645301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*